Page 151 - 南京医科大学自然版

第45卷第1期 马 萍，洪 鸣. 急性髓系白血病一线诱导方案相关进展［J］.
2025年1月 南京医科大学学报（自然科学版），2025，45（1）：139-146 ·145 ·

［参考文献］ ［11］SUO X，ZHENG F，WANG D，et al. Venetoclax combined
with daunorubicin and cytarabine（2+6）as induction treat⁃
［1］ 中华医学会血液学分会白血病淋巴瘤学组. 成人急性
ment in adults with newly diagnosed acute myeloid leuke⁃
髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南
mia：a phase 2，multicenter，single⁃arm trial［J］. Exp He⁃
（2023年版）［J］. 中华血液学杂志，2023，44（09）：705-712
matol Oncol，2023，12（1）：45
Leukemia and Lymphoma Group，Hematology Branch，
［12］DÖHNER H，WEI A H，APPELBAUM F R，et al. Diagno⁃
Chinese Medical Association. Chinese Diagnosis and
sis and management of AML in adults：2022 recommenda⁃
treatment guidelines for adult acute myeloid leukemia
tions from an international expert panel on behalf of the
（non acute promyelocytic leukemia）（2023 Edition）［J］.
ELN［J］. Blood，2022，140（12）：1345-1377
Chinese Journal of Hematology，2023，44（09）：705-712
［13］DINARDO C D，LACHOWIEZ C A，TAKAHASHI K，et
［2］ SALEH K，KHALIFEH⁃SALEH N，KOURIE H R. Acute
al. Venetoclax combined with FLAG⁃IDA induction and
myeloid leukemia transformed to a targetable disease［J］.
consolidation in newly diagnosed and relapsed or refracto⁃
Future Oncol，2020，16（14）：961-972
ry acute myeloid leukemia［J］. J Clin Oncol，2021，39
［3］ JONESC L，STEVENS B M，D’ALESSANDRO A，et al.
（25）：2768-2778
Inhibition of amino acid metabolism selectively targets hu⁃
［14］KADIA T M，REVILLE P K，BORTHAKUR G，et al.
man leukemia stem cells［J］. Cancer Cell，2019，35（2）： Venetoclax plus intensive chemotherapy with cladribine，
333-335 idarubicin，and cytarabine in patients with newly diag⁃
［4］ POLLYEA D A，STEVENS B M，JONES C L，et al. Vene⁃
nosed acute myeloid leukaemia or high⁃risk myelodysplas⁃
toclax with azacitidine disrupts energy metabolism and tic syndrome：a cohort from a single⁃centre，single⁃arm，
targets leukemia stem cells in patients with acute myeloid
phase 2 trial［J］. Lancet Haematol，2021，8（8）：e552-e561
leukemia［J］. Nat Med，2018，24（12）：1859-1866
［15］KEREN ⁃ FROIM N，HEERING G，SHARVIT G，et al.
［5］ 尹金玉，徐子瑶，孙 倩，等. 维奈克拉联合地西他滨、阿 ELN 2017 classification significantly impacts the risk of
柔比星对急性髓系白血病细胞增殖和凋亡的影响［J］. 南京 early death in acute myeloid leukemia patients receiving
医科大学学报（自然科学版），2022，42（10）：1349-1356 intensive induction chemotherapy［J］. Ann Hematol，
YIN J Y，XU Z Y，SUN Q，et al. The effect of combination 2022，101（2）：309-316
therapy with venetoclax，decitabine，and doxorubicin on ［16］XIE J，BAO X，XUE S L，et al. Venetoclax with decitabi⁃
proliferation and apoptosis of acute myeloid leukemia ne as frontline treatment in younger adults with newly di⁃
cells［J］. Journal of Nanjing Medical University（Natural agnosed ELN adverse ⁃ risk AML［J］. Blood，2023，142
Sciences），2022，42（10）：1349-1356 （15）：1323-1327
［6］ DINARDO C D，PRATZ K，PULLARKAT V，et al. Veneto⁃ ［17］CHUA C C，ROBERTS A W，REYNOLDS J，et al. Chemo⁃
clax combined with decitabine or azacitidine in treatment⁃ therapy and venetoclax in elderly acute myeloid leukemia
naive，elderly patients with acute myeloid leukemia［J］. trial（CAVEAT）：a phase Ib dose⁃escalation study of veneto⁃
Blood，2019，133（1）：7-17 clax combined with modified intensive chemotherapy［J］.
［7］ DINARDO C D，JONAS B A，PULLARKATV，et al. Azacit⁃ J Clin Oncol，2020，38（30）：3506-3517
idine and venetoclax in previously untreated acute myeloid ［18］TENOLD M E，MOSKOFF B N，KRISHNAN R，et al. Ret⁃
leukemia［J］. N Engl J Med，2020，383（7）：617-629 rospective analysis of adult patients with relapsed/refrac⁃
［8］ WEI A H，MONTESINOS P，IVANOV V，et al. Veneto⁃ tory acute myeloid leukemia treated with FLAG at a com⁃
clax plus LDAC for newly diagnosed AML ineligible for prehensive cancer center［J］. Clin Lymphoma Myeloma
intensive chemotherapy：a phase 3 randomized placebo ⁃ Leuk，2021，21（7）：e611-e618
controlled trial［J］. Blood，2020，135（24）：2137-2145 ［19］SOLH M M，SOLOMON S R，MORRIS L E，et al. Im⁃
［9］ LEE J H，KIM H，JOO Y D，et al. Prospective randomized proved post remission survival of non ⁃ favorable risk
comparison of idarubicin and high⁃dose daunorubicin in acute myelogenous leukemia（AML）patients following ini⁃
induction chemotherapy for newly diagnosed acute myeloid tial remission induction therapy with FLAG+/-idarubicin
leukemia［J］. J Clin Oncol，2017，35（24）：2754-2763 versus 3 + 7（anthracycline + cytarabine）［J］. Leuk Res，
［10］WANG H，MAO L，YANG M，et al. Venetoclax plus 3+7 2020，93：106318
daunorubicin and cytarabine chemotherapy as first ⁃ line ［20］POLLYEA D A，PRATZ K，LETAI A，et al. Venetoclax
treatment for adults with acute myeloid leukaemia：a mul⁃ with azacitidine or decitabine in patients with newly diag⁃
ticentre，single⁃arm，phase 2 trial［J］. Lancet Haematol， nosed acute myeloid leukemia：long term follow⁃up from a
2022，9（6）：e415-e424 phase 1b study［J］. Am J Hematol，2021，96（2）：208-217